Glioblastoma is the most common malignant brain cancer in adults, with poor prognosis. The blood-brain barrier limits the arrival of several promising anti-glioblastoma drugs, and restricts the design of efficient therapies. Recently, by using state-of-the-art technologies, including thymidine kinase targeting system in combination with glioblastoma xenograft mouse models, it was revealed that targeting glioblastoma-derived pericytes improves chemotherapy efficiency. Strikingly, ibrutinib treatment enhances chemotherapeutic effectiveness, by targeting pericytes, improving blood-brain barrier permeability, and prolonging survival. This study identifies glioblastoma-derived pericyte as a novel target in the brain tumor microenvironment during carcinogenesis. Here, we summarize and evaluate recent advances in the understanding of pericyte's role in the glioblastoma microenvironment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6238207 | PMC |
| http://dx.doi.org/10.1007/s10456-018-9621-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development and Biological Characterization of Cancer Biomimetic Membrane Nanovesicles for Enhancing Therapy Efficacy in Human Glioblastoma Cells.
Nanomaterials (Basel)
November 2024
Department of Biology and Biotechnology, University of Pavia, 27100 Pavia, Italy.
As nanocarriers of a new generation, biomimetic nanovesicles are an emerging class of therapeutic tools whose surface is integrated or fabricated with biomaterials capable of mimicking the biological features and functions of native cells. Thanks to this, biomimetic nanovesicles, in particular, those made by plasma membrane moieties, possess greatly improved biocompatibility, high target specificity, a long retention time, and minimal undesired immune responses. For these reasons, a multitude of progenitor cells including cancer ones were employed as templates to generate biomimetic or membrane-camouflaged nanovesicles hosting different therapeutic compounds.
View Article and Find Full Text PDFImplications of glioblastoma-derived exosomes in modifying the immune system: state-of-the-art and challenges.
Rev Neurosci
November 2024
Research Center for Immunodeficiencies, Children's Medical Center, 48439 Tehran University of Medical Sciences, Tehran, 1416634793, Iran.
Glioblastoma is a brain cancer with a poor prognosis. Failure of classical chemotherapy and surgical treatments indicates that new therapeutic approaches are needed. Among cell-free options, exosomes are versatile extracellular vesicles (EVs) that carry important cargo across barriers such as the blood-brain barrier (BBB) to their target cells.
View Article and Find Full Text PDFProteomics Studies on Extracellular Vesicles Derived from Glioblastoma: Where Do We Stand?
Int J Mol Sci
September 2024
Department of Innovative Technologies in Medicine and Dentistry, 'G. D'Annunzio' University of Chieti-Pescara, Via Vestini 31, 66100 Chieti, Italy.
Article Synopsis
- Glioblastoma multiforme (GBM) releases extracellular vesicles (EVs) that can transfer aggressive traits to other cells, making the study of these vesicles crucial for understanding tumor behavior.
- * EV proteins are being investigated to find new biomarkers and targets for treatment, with proteomic studies primarily using "bottom-up" mass spectrometry on EVs from GBM cells and patient fluids.
- * Despite identifying many dysregulated proteins, clinical translation is challenging due to inconsistent EV isolation methods and proteome analysis, highlighting the need for standardized techniques and exploring protein mutations to improve GBM therapies.*
Human glioblastoma-derived cell membrane nanovesicles: a novel, cell-specific strategy for boron neutron capture therapy of brain tumors.
Sci Rep
August 2024
Department of Pharmacy, University of Genoa, 16148, Genoa, Italy.
Article Synopsis
- Glioblastoma (GBM) is a highly aggressive brain tumor that represents about 50% of primary malignant CNS tumors, necessitating the development of new treatment options.
- Boron neutron capture therapy shows promise for treating high-grade gliomas and involves delivering sodium borocaptate (BSH) specifically to GBM cells using cell membrane-derived vesicles (CMVs).
- CMVs, made from patient-derived GBM stem-like cell membranes, effectively target GBM cells, have low cytotoxicity, and demonstrate successful loading of BSH through different methods, indicating their potential for GBM therapy.
EphA3 CAR T cells are effective against glioblastoma in preclinical models.
J Immunother Cancer
August 2024
QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia
Background: Adoptive T-cell therapy targeting antigens expressed in glioblastoma has emerged as a potential therapeutic strategy to prevent or delay recurrence and prolong overall survival in this aggressive disease setting. Ephrin receptor A3 (EphA3), which is highly expressed in glioblastoma; in particular, on the tumor vasculature and brain cancer stem cells, is an ideal target for immune-based therapies.
Methods: We have designed an EphA3-targeted chimeric antigen receptor (CAR) using the single chain variable fragment of a novel monoclonal antibody, and assessed its therapeutic potential against EphA3-expressing patient-derived glioblastoma neurospheres, organoids and xenografted glioblastoma tumors in immunodeficient mice.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!